|
ZCRB1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.18000001278784E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.73350000026917E-07 |
| Normal-vs-Stage2 |
9.826100E-04 |
| Normal-vs-Stage3 |
3.63919999690765E-08 |
| Normal-vs-Stage4 |
7.05890013108501E-10 |
| Stage1-vs-Stage2 |
5.989800E-01 |
| Stage1-vs-Stage3 |
2.878000E-01 |
| Stage1-vs-Stage4 |
3.611600E-02 |
| Stage2-vs-Stage3 |
2.584800E-01 |
| Stage2-vs-Stage4 |
4.176300E-02 |
| Stage3-vs-Stage4 |
2.193400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.50870049365449E-10 |
| Normal-vs-AfricanAmerican |
4.769100E-04 |
| Normal-vs-Asian |
1.477870E-03 |
| Caucasian-vs-AfricanAmerican |
8.338800E-01 |
| Caucasian-vs-Asian |
1.325220E-01 |
| AfricanAmerican-vs-Asian |
4.507800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.30339999588381E-09 |
| Normal-vs-Female |
3.37619999735139E-08 |
| Male-vs-Female |
1.021230E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.99450000246426E-08 |
| Normal-vs-Age(41-60Yrs) |
2.4730000003359E-07 |
| Normal-vs-Age(61-80Yrs) |
3.19990000052783E-08 |
| Normal-vs-Age(81-100Yrs) |
7.010800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.936200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.087600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.211000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.311600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.343200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.038800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.357000E-01 |
| Classical-VS-Follicular |
2.852200E-02 |
| Classical-VS-Other |
8.902800E-01 |
| Classical-VS-Normal |
7.76569997196219E-09 |
| Tall-VS-Follicular |
8.220400E-02 |
| Tall-VS-Other |
8.668200E-01 |
| Tall-VS-Normal |
1.81121999999201E-05 |
| Follicular-VS-Other |
4.259000E-01 |
| Follicular-VS-Normal |
5.299100E-03 |
| Other-VS-Normal |
1.233970E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.40149999780814E-08 |
| Normal-vs-N1 |
1.51862999999697E-05 |
| N0-vs-N1 |
7.564800E-01 |
|
|
